MDM2 Promotes Cell Motility and Invasiveness by Regulating E-Cadherin Degradation

REFERENCES

• Aguilar, R. C., and B. Wendland. 2005. Endocytosis of membrane receptors: two pathways are better than one. Proc. Natl. Acad. Sci. USA 102:2679–2680.
   PubMed Web of Science ®Google Scholar
• Aguilar, R. C., and B. Wendland. 2003. Ubiquitin: not just for proteasomes anymore. Curr. Opin. Cell Biol. 15:184–190.
   PubMed Web of Science ®Google Scholar
• Antonelli, A., R. Crinelli, M. Bianchi, A. Cerasi, L. Gentilini, G. Serafini, and M. Magnani. 1999. Efficient inhibition of macrophage TNF-alpha production upon targeted delivery of K48R ubiquitin. Br. J. Haematol. 104:475–481.
   PubMed Web of Science ®Google Scholar
• Arora, S., R. Mathew, M. Mathur, T. K. Chattopadhayay, and R. Ralhan. 2001. Alterations in MDM2 expression in esophageal squamous cell carcinoma: relationship with p53 status. Pathol. Oncol. Res. 7:203–208.
   PubMedGoogle Scholar
• Bardeesy, N., D. Falkoff, M. J. Petruzzi, N. Nowak, B. Zabel, M. Adam, M. C. Aguiar, P. Grundy, T. Shows, and J. Pelletier. 1994. Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat. Genet. 7:91–97.
   PubMed Web of Science ®Google Scholar
• Bartel, F., H. Taubert, and L. C. Harris. 2002. Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell 2:9–15.
   PubMed Web of Science ®Google Scholar
• Benmerah, A., C. Lamaze, B. Begue, S. L. Schmid, A. Dautry-Varsat, and N. Cerf-Bensussan. 1998. AP-2/Eps15 interaction is required for receptor-mediated endocytosis. J. Cell Biol. 140:1055–1062.
   PubMed Web of Science ®Google Scholar
• Berx, G., A. M. Cleton-Jansen, F. Nollet, W. J. de Leeuw, M. van de Vijver, C. Cornelisse, and F. van Roy. 1995. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J. 14:6107–6115.
   PubMed Web of Science ®Google Scholar
• Birchmeier, W., and J. Behrens. 1994. Cadherin expression in carcinomas: role in the formation of cell junctions and the prevention of invasiveness. Biochim. Biophys. Acta 1198:11–26.
   PubMed Web of Science ®Google Scholar
• Bolos, V., H. Peinado, M. A. Perez-Moreno, M. F. Fraga, M. Esteller, and A. Cano. 2003. The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J. Cell Sci. 116:499–511.
   PubMed Web of Science ®Google Scholar
• Bomsel, M., R. Parton, S. A. Kuznetsov, T. A. Schroer, and J. Gruenberg. 1990. Microtubule- and motor-dependent fusion in vitro between apical and basolateral endocytic vesicles from MDCK cells. Cell 62:719–731.
   PubMedGoogle Scholar
• Brodsky, F. M., C. Y. Chen, C. Knuehl, M. C. Towler, and D. E. Wakeham. 2001. Biological basket weaving: formation and function of clathrin-coated vesicles. Annu. Rev. Cell Dev. Biol. 17:517–568.
   PubMedGoogle Scholar
• Cao, H., F. Garcia, and M. A. McNiven. 1998. Differential distribution of dynamin isoforms in mammalian cells. Mol. Biol. Cell 9:2595–2609.
   PubMed Web of Science ®Google Scholar
• Cao, H., H. M. Thompson, E. W. Krueger, and M. A. McNiven. 2000. Disruption of Golgi structure and function in mammalian cells expressing a mutant dynamin. J. Cell Sci. 113:1993–2002.
   PubMedGoogle Scholar
• Chan, J. K., and C. S. Wong. 2001. Loss of E-cadherin is the fundamental defect in diffuse-type gastric carcinoma and infiltrating lobular carcinoma of the breast. Adv. Anat. Pathol. 8:165–172.
   PubMed Web of Science ®Google Scholar
• Chen, H., and P. De Camilli. 2005. The association of epsin with ubiquitinated cargo along the endocytic pathway is negatively regulated by its interaction with clathrin. Proc. Natl. Acad. Sci. USA 102:2766–2771.
   PubMedGoogle Scholar
• Chen, H., S. Fre, V. I. Slepnev, M. R. Capua, K. Takei, M. H. Butler, P. P. Di Fiore, and P. De Camilli. 1998. Epsin is an EH-domain-binding protein implicated in clathrin-mediated endocytosis. Nature 394:793–797.
   PubMed Web of Science ®Google Scholar
• Cheng, C. W., P. E. Wu, J. C. Yu, C. S. Huang, C. T. Yue, C. W. Wu, and C. Y. Shen. 2001. Mechanisms of inactivation of E-cadherin in breast carcinoma: modification of the two-hit hypothesis of tumor suppressor gene. Oncogene 20:3814–3823.
   PubMed Web of Science ®Google Scholar
• Christofori, G., and H. Semb. 1999. The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem. Sci. 24:73–76.
   PubMed Web of Science ®Google Scholar
• Confalonieri, S., A. E. Salcini, C. Puri, C. Tacchetti, and P. P. Di Fiore. 2000. Tyrosine phosphorylation of Eps15 is required for ligand-regulated, but not constitutive, endocytosis. J. Cell Biol. 150:905–912.
   PubMedGoogle Scholar
• Damke, H., T. Baba, D. E. Warnock, and S. L. Schmid. 1994. Induction of mutant dynamin specifically blocks endocytic coated vesicle formation. J. Cell Biol. 127:915–934.
   PubMedGoogle Scholar
• Damke, H., D. D. Binns, H. Ueda, S. L. Schmid, and T. Baba. 2001. Dynamin GTPase domain mutants block endocytic vesicle formation at morphologically distinct stages. Mol. Biol. Cell 12:2578–2589.
   PubMedGoogle Scholar
• Datta, M. W., E. Macri, S. Signoretti, A. A. Renshaw, and M. Loda. 2001. Transition from in situ to invasive testicular germ cell neoplasia is associated with the loss of p21 and gain of mdm-2 expression. Mod. Pathol. 14:437–442.
   PubMedGoogle Scholar
• Dei Tos, A. P., C. Doglioni, S. Piccinin, R. Sciot, A. Furlanetto, M. Boiocchi, P. Dal Cin, R. Maestro, C. D. Fletcher, and G. Tallini. 2000. Coordinated expression and amplification of the MDM2, CDK4, and HMGI-C genes in atypical lipomatous tumours. J. Pathol. 190:531–536.
   PubMed Web of Science ®Google Scholar
• Fontana, X., P. Ferrari, M. Abbes, J. Monticelli, M. Namer, and F. Bussiere. 1994. Study of mdm2 gene amplification in primary breast tumors. Bull. Cancer 81:587–592. (In French.)
   PubMedGoogle Scholar
• Ford, M. G., I. G. Mills, B. J. Peter, Y. Vallis, G. J. Praefcke, P. R. Evans, and H. T. McMahon. 2002. Curvature of clathrin-coated pits driven by epsin. Nature 419:361–366.
   PubMed Web of Science ®Google Scholar
• Fridman, J. S., E. Hernando, M. T. Hemann, E. de Stanchina, C. Cordon-Cardo, and S. W. Lowe. 2003. Tumor promotion by Mdm2 splice variants unable to bind p53. Cancer Res. 63:5703–5706.
   PubMedGoogle Scholar
• Fujita, Y., G. Krause, M. Scheffner, D. Zechner, H. E. Leddy, J. Behrens, T. Sommer, and W. Birchmeier. 2002. Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex. Nat. Cell Biol. 4:222–231.
   PubMed Web of Science ®Google Scholar
• Giri, D. K., M. Ali-Seyed, L. Y. Li, D. F. Lee, P. Ling, G. Bartholomeusz, S. C. Wang, and M. C. Hung. 2005. Endosomal transport of ErbB-2: mechanism for nuclear entry of the cell surface receptor. Mol. Cell. Biol. 25:11005–11018.
   PubMed Web of Science ®Google Scholar
• Girnita, L., A. Girnita, and O. Larsson. 2003. Mdm2-dependent ubiquitination and degradation of the insulin-like growth factor 1 receptor. Proc. Natl. Acad. Sci. USA 100:8247–8252.
   PubMed Web of Science ®Google Scholar
• Harris, L. C. 2005. MDM2 splice variants and their therapeutic implications. Curr. Cancer Drug Targets 5:21–26.
   PubMed Web of Science ®Google Scholar
• Haupt, Y., R. Maya, A. Kazaz, and M. Oren. 1997. Mdm2 promotes the rapid degradation of p53. Nature 387:296–299.
   PubMed Web of Science ®Google Scholar
• He, T. C., S. Zhou, L. T. da Costa, J. Yu, K. W. Kinzler, and B. Vogelstein. 1998. A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. USA 95:2509–2514.
   PubMed Web of Science ®Google Scholar
• Henley, J. R., E. W. Krueger, B. J. Oswald, and M. A. McNiven. 1998. Dynamin-mediated internalization of caveolae. J. Cell Biol. 141:85–99.
   PubMed Web of Science ®Google Scholar
• Hicke, L., and R. Dunn. 2003. Regulation of membrane protein transport by ubiquitin and ubiquitin-binding proteins. Annu. Rev. Cell Dev. Biol. 19:141–172.
   PubMed Web of Science ®Google Scholar
• Honda, R., H. Tanaka, and H. Yasuda. 1997. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 420:25–27.
   PubMed Web of Science ®Google Scholar
• Honda, R., and H. Yasuda. 2000. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase. Oncogene 19:1473–1476.
   PubMed Web of Science ®Google Scholar
• Honda, R., and H. Yasuda. 1999. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53. EMBO J. 18:22–27.
   PubMed Web of Science ®Google Scholar
• Ikeguchi, M., T. Ueda, K. Fukuda, K. Yamaguchi, S. Tsujitani, and N. Kaibara. 2002. Expression of the murine double minute gene 2 oncoprotein in esophageal squamous cell carcinoma as a novel marker for lack of response to chemoradiotreatment. Am. J. Clin. Oncol. 25:454–459.
   PubMed Web of Science ®Google Scholar
• Iwakuma, T., and G. Lozano. 2003. MDM2, an introduction. Mol. Cancer Res. 1:993–1000.
   PubMed Web of Science ®Google Scholar
• Jiang, W. G., and R. E. Mansel. 2000. E-cadherin complex and its abnormalities in human breast cancer. Surg. Oncol. 9:151–171.
   PubMedGoogle Scholar
• Kim, K. J., B. Li, J. Winer, M. Armanini, N. Gillett, H. S. Phillips, and N. Ferrara. 1993. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841–844.
   PubMed Web of Science ®Google Scholar
• Koga, T., S. Hashimoto, K. Sugio, I. Yoshino, K. Nakagawa, Y. Yonemitsu, K. Sugimachi, and K. Sueishi. 2001. Heterogeneous distribution of P53 immunoreactivity in human lung adenocarcinoma correlates with MDM2 protein expression, rather than with P53 gene mutation. Int. J. Cancer 95:232–239.
   PubMed Web of Science ®Google Scholar
• Korkolopoulou, P., P. Christodoulou, P. Kapralos, M. Exarchakos, A. Bisbiroula, M. Hadjiyannakis, C. Georgountzos, and E. Thomas-Tsagli. 1997. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer. Pathol. Res. Pract. 193:767–775.
   PubMed Web of Science ®Google Scholar
• Kubbutat, M. H., S. N. Jones, and K. H. Vousden. 1997. Regulation of p53 stability by Mdm2. Nature 387:299–303.
   PubMed Web of Science ®Google Scholar
• Ladanyi, M., C. Cha, R. Lewis, S. C. Jhanwar, A. G. Huvos, and J. H. Healey. 1993. MDM2 gene amplification in metastatic osteosarcoma. Cancer Res. 53:16–18.
   PubMed Web of Science ®Google Scholar
• Leptin, M. 1991. twist and snail as positive and negative regulators during Drosophila mesoderm development. Genes Dev. 5:1568–1576.
   PubMedGoogle Scholar
• Li, Y. M., Y. Pan, Y. Wei, X. Cheng, B. P. Zhou, M. Tan, X. Zhou, W. Xia, G. N. Hortobagyi, D. Yu, and M. C. Hung. 2004. Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell 6:459–469.
   PubMed Web of Science ®Google Scholar
• Lo, H. W., S. C. Hsu, M. Ali-Seyed, M. Gunduz, W. Xia, Y. Wei, G. Bartholomeusz, J. Y. Shih, and M. C. Hung. 2005. Nuclear interaction of EGFR and STAT3 in the activation of the iNOS/NO pathway. Cancer Cell 7:575–589.
   PubMed Web of Science ®Google Scholar
• Lukas, J., D. Q. Gao, M. Keshmeshian, W. H. Wen, D. Tsao-Wei, S. Rosenberg, and M. F. Press. 2001. Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. Cancer Res. 61:3212–3219.
   PubMed Web of Science ®Google Scholar
• Lyakhovich, A., and M. P. Shekhar. 2003. Supramolecular complex formation between Rad6 and proteins of the p53 pathway during DNA damage-induced response. Mol. Cell. Biol. 23:2463–2475.
   PubMed Web of Science ®Google Scholar
• Mathew, R., S. Arora, R. Khanna, M. Mathur, N. K. Shukla, and R. Ralhan. 2002. Alterations in p53 and pRb pathways and their prognostic significance in oesophageal cancer. Eur. J. Cancer 38:832–841.
   PubMed Web of Science ®Google Scholar
• McCann, A. H., A. Kirley, D. N. Carney, N. Corbally, H. M. Magee, G. Keating, and P. A. Dervan. 1995. Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status. Br. J. Cancer 71:981–985.
   PubMed Web of Science ®Google Scholar
• Momand, J., D. Jung, S. Wilczynski, and J. Niland. 1998. The MDM2 gene amplification database. Nucleic Acids Res. 26:3453–3459.
   PubMed Web of Science ®Google Scholar
• Moore, L., S. Venkatachalam, H. Vogel, J. C. Watt, C. L. Wu, H. Steinman, S. N. Jones, and L. A. Donehower. 2003. Cooperativity of p19ARF, Mdm2, and p53 in murine tumorigenesis. Oncogene 22:7831–7837.
   PubMedGoogle Scholar
• Morgan, R. J., P. V. Newcomb, R. H. Hardwick, and D. Alderson. 1999. Amplification of cyclin D1 and MDM-2 in oesophageal carcinoma. Eur. J. Surg. Oncol. 25:364–367.
   PubMedGoogle Scholar
• Nieto, M. A. 2002. The snail superfamily of zinc-finger transcription factors. Nat. Rev. Mol. Cell Biol. 3:155–166.
   PubMed Web of Science ®Google Scholar
• Osman, I., M. Drobnjak, M. Fazzari, J. Ferrara, H. I. Scher, and C. Cordon-Cardo. 1999. Inactivation of the p53 pathway in prostate cancer: impact on tumor progression. Clin. Cancer Res. 5:2082–2088.
   PubMed Web of Science ®Google Scholar
• Palacios, F., J. S. Tushir, Y. Fujita, and C. D'Souza-Schorey. 2005. Lysosomal targeting of E-cadherin: a unique mechanism for the down-regulation of cell-cell adhesion during epithelial to mesenchymal transitions. Mol. Cell. Biol. 25:389–402.
   PubMedGoogle Scholar
• Paterson, A. D., R. G. Parton, C. Ferguson, J. L. Stow, and A. S. Yap. 2003. Characterization of E-cadherin endocytosis in isolated MCF-7 and Chinese hamster ovary cells: the initial fate of unbound E-cadherin. J. Biol. Chem. 278:21050–21057.
   PubMedGoogle Scholar
• Saito, H., S. Tsujitani, S. Oka, M. Ikeguchi, M. Maeta, and N. Kaibara. 2002. The expression of murine double minute 2 is a favorable prognostic marker in esophageal squamous cell carcinoma without p53 protein accumulation. Ann. Surg. Oncol. 9:450–456.
   PubMedGoogle Scholar
• Shenoy, S. K., P. H. McDonald, T. A. Kohout, and R. J. Lefkowitz. 2001. Regulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestin. Science 294:1307–1313.
   PubMed Web of Science ®Google Scholar
• Sigismund, S., T. Woelk, C. Puri, E. Maspero, C. Tacchetti, P. Transidico, P. P. Di Fiore, and S. Polo. 2005. Clathrin-independent endocytosis of ubiquitinated cargos. Proc. Natl. Acad. Sci. USA 102:2760–2765.
   PubMed Web of Science ®Google Scholar
• Skoudy, A., M. D. Llosas, and A. Garcia de Herreros. 1996. Intestinal HT-29 cells with dysfunction of E-cadherin show increased pp60src activity and tyrosine phosphorylation of p120-catenin. Biochem. J. 317:279–284.
   PubMedGoogle Scholar
• Steinman, H. A., E. Burstein, C. Lengner, J. Gosselin, G. Pihan, C. S. Duckett, and S. N. Jones. 2004. An alternative splice form of Mdm2 induces p53-independent cell growth and tumorigenesis. J. Biol. Chem. 279:4877–4886.
   PubMedGoogle Scholar
• Strous, G. J., and J. A. Schantl. 2001. Beta-arrestin and Mdm2, unsuspected partners in signaling from the cell surface. Sci. STKE 2001:PE41.
   PubMedGoogle Scholar
• Swaroop, M., and Y. Sun. 2003. Mdm2 ligase dead mutants did not act in a dominant negative manner to re-activate p53, but promoted tumor cell growth. Anticancer Res. 23:3167–3174.
   PubMedGoogle Scholar
• Takahashi, Y., Y. Kitadai, C. D. Bucana, K. R. Cleary, and L. M. Ellis. 1995. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 55:3964–3968.
   PubMed Web of Science ®Google Scholar
• Takeichi, M. 1993. Cadherins in cancer: implications for invasion and metastasis. Curr. Opin. Cell Biol. 5:806–811.
   PubMed Web of Science ®Google Scholar
• Tan, M., J. Yao, and D. Yu. 1997. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res. 57:1199–1205.
   PubMed Web of Science ®Google Scholar
• Thiery, J. P. 2003. Epithelial-mesenchymal transitions in development and pathologies. Curr. Opin. Cell Biol. 15:740–746.
   PubMed Web of Science ®Google Scholar
• Thiery, J. P., and D. Chopin. 1999. Epithelial cell plasticity in development and tumor progression. Cancer Metast. Rev. 18:31–42.
   PubMed Web of Science ®Google Scholar
• Vargas, D. A., S. Takahashi, and Z. Ronai. 2003. Mdm2: a regulator of cell growth and death. Adv. Cancer Res. 89:1–34.
   PubMedGoogle Scholar
• Vassilev, L. T., B. T. Vu, B. Graves, D. Carvajal, F. Podlaski, Z. Filipovic, N. Kong, U. Kammlott, C. Lukacs, C. Klein, N. Fotouhi, and E. A. Liu. 2004. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303:844–848.
   PubMed Web of Science ®Google Scholar
• Xia, W., J. S. Chen, X. Zhou, P. R. Sun, D. F. Lee, Y. Liao, B. P. Zhou, and M. C. Hung. 2004. Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin. Cancer Res. 10:3815–3824.
   PubMed Web of Science ®Google Scholar
• Zauberman, A., D. Flusberg, Y. Haupt, Y. Barak, and M. Oren. 1995. A functional p53-responsive intronic promoter is contained within the human mdm2 gene. Nucleic Acids Res. 23:2584–2592.
   PubMed Web of Science ®Google Scholar
• Zhang, L., and R. P. Hill. 2004. Hypoxia enhances metastatic efficiency by up-regulating Mdm2 in KHT cells and increasing resistance to apoptosis. Cancer Res. 64:4180–4189.
   PubMed Web of Science ®Google Scholar
• Zhou, B. P., J. Deng, W. Xia, J. Xu, Y. M. Li, M. Gunduz, and M. C. Hung. 2004. Dual regulation of Snail by GSK-3beta-mediated phosphorylation in control of epithelial-mesenchymal transition. Nat. Cell Biol. 6:931–940.
   PubMed Web of Science ®Google Scholar
• Zhou, B. P., Y. Liao, W. Xia, Y. Zou, B. Spohn, and M. C. Hung. 2001. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat. Cell Biol. 3:973–982.
   PubMed Web of Science ®Google Scholar
• Zietz, C., M. Rossle, C. Haas, A. Sendelhofert, A. Hirschmann, M. Sturzl, and U. Lohrs. 1998. MDM-2 oncoprotein overexpression, p53 gene mutation, and VEGF up-regulation in angiosarcomas. Am. J. Pathol. 153:1425–1433.
   PubMed Web of Science ®Google Scholar